|
Keynote Forum |
|
|
Day 1: Morning, July. 15, 2022 |
|
|
Moderator2 |
Dr. Mattias von Herrath, Vice President/Head NovoNordisk; Professor/Director of the Diabetes Center, La Jolla Institute, USA |
|
Time |
Speeches and Speakers |
|
09:00-09:05 |
Chair's Introduction |
|
09:05-09:30 |
Title: Tankyraseinhibitors: Evidence for Therapeutic Potential in Immuno-oncology Dr. Luc Van Hijfte, SVP Medicinal Chemistry, Symeres, the Netherlands |
|
09:30-09:55 |
Title: TBD Dr. Mattias von Herrath, Vice President/Head NovoNordisk; Professor/Director of the Diabetes Center, La Jolla Institute, USA |
|
09:55-10:20 |
Title: Nanoparticles for Gene and Drug Delivery: Applying Light Scattering to Screening and Characterization Dr. Daniel Some, Principal Scientist, Wyatt Technology Corporation, USA |
|
10:20-10:45 |
Title: The Role of ABC Membrane Transporters in Personalized Diagnostics and Drug Treatment Dr. Balazs Sarkadi, Professor, Semmelweis University, Hungary |
|
10:45-11:10 |
Title: Next Generation T Cell Therapy Products Partnering with Pfizer – Introduction to Emerging Science & Innovation Dr. Uwe Schoenbeck, Senior Vice President & Chief Scientific Officer, Worldwide R & D, Pfizer, USA |
|
11:10-11:35 |
Title: New Innovative Ways to Enhance Treatment Targeting and Individualization: The Complementary Use of Predicting Modeling and Machine Learning in the Field of Diabetes and Metabolic Disorders Dr. Zsolt Bosnyak, VP, Global Medical Head Diabetes, Sanofi, France |
|
Session 211: Pharmacogenetics, Pharmacogenomics and Precision Medicine |
|
|
Day 1: Afternoon, July. 15, 2022 |
|
|
Chair |
Dr. Godefridus J Peters, Professor in Pharmacology of Cytostatics, Amsterdam University Medical Centers, the Netherlands; Professor in Biochemistry, Medical University of Gdansk, Poland |
| Co-Chair | Dr. Hongtao Xiao, Professor, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, China |
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:05 |
Keynote Speech Title: Personalized and Precision Medicine (PPM) as a Unique Healthcare Model to be Set Up via Translational Applications and Upgraded Business Modeling to Secure the Human Healthcare, Wellness and Biosafety Dr. Sergey Suchkov, Professor, Director, Center for Personalized Medicine, I.M. Sechenov First Moscow State Medical University, Russia |
|
14:05-14:30 |
Title: The Role of Pharmacogenetics and Drug Discovery Dr. Godefridus J Peters, Professor in Pharmacology of Cytostatics, Amsterdam University Medical Centers, the Netherlands; Professor in Biochemistry, Medical University of Gdansk, Poland |
|
14:30-14:55 |
Title: Testing Complex Activity Profiles of Human Immune Cell using a Highly Standardised Bed-side Whole Blood Culture Model Dr. Manfred Schmolz, CEO/CSO, HOT Screen GmbH, Germany |
|
14:55-15:20 |
Title: The Influence of MTHFR Genetic Polymorphisms on Adverse Reactions after Methotrexate in Patients with Hematological Malignancies Dr. Hongtao Xiao, Professor, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, China |
|
15:20-15:30 |
Coffee Break |
| 15:30-15:55 |
Title: Optimized and Fully Characterized Drugs Together with Disease Understanding: De-risking Clinical Development Dr. Charlotte Kopitz, EVP, Head of Therapeutic Research, Nuvisan Pharma Services Group, Germany |
| 15:55-16:20 |
Title: Precision Medicine at the Interface of Translational Research and Systems Medicine Dr. Kristel Van Steen, Professor, University of Liege/KU Leuven, Belgium |
| 16:20-16:45 |
Title: Disease Modeling of Heart Failure: Rare Diseases and SARS-CoV-2 Infection Dr. Tetsuro Wakatsuki, Chief Scientific Officer, InvivoSciences, Inc., USA |
| 16:45-17:10 |
Speech Opportunity Available |
|
Session 221: Innovative Drug Discovery Technology |
|
|
Day 1: Afternoon, July. 15, 2022 |
|
|
Chair |
Dr. Alexey RAK, Director of Bio Structure and Biophysics, Sanofi R&D, France |
| Co-chair |
Dr. Barry Morgan, CSO, Hitgen Ltd., USA
|
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-13:55 |
Title: TBD Dr. Alexey RAK, Director of Bio Structure and Biophysics, Sanofi R&D, France |
|
13:55-14:15 |
Speech Opportunity Available
Abstract and Biography: Submit Here |
|
14:15-14:35 |
Title: Cold Chain Options for Cryopreservation and Transport of Natural and Bioengineered Tissues Dr. Kelvin Brockbank, Chief Executive Officer, Tissue Testing Technologies LLC, USA |
|
14:35-14:55 |
Title: Assays, Biophysics and Structural Biology towards Drugs with Innovative Inhibition Mode Dr. Lars Neumann, Director Assays, Biophysics & Screening, Proteros biostructures GmbH, Germany |
| 14:55-15:15 |
Title: The Importance of Physicochemical Properties for the Bioavailability of Pharmaceutical Compounds Dr. Rebeca Ruiz, Global Analytical Services Manager, Sirius Analytical Instruments Ltd, UK |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:50 |
Title: Demystifying DEL: DNA Encoded Library Technology is not (that) Complicated! Dr. Barry Morgan, CSO, Hitgen Ltd., USA |
|
15:50-16:10 |
Title: Application of an Antibiotic-free Selection System and Use of an AI-assisted Process Optimization Approach Dr. Marinka Gudelj-Wyletal, Scientist, Process Science & Upstream Development, Boehringer Ingelheim RCV GmbH & Co KG, Austria |
|
16:10-16:30 |
Title: Machine Learning Enabled Epitope Selective Antibody Discovery: Epitopes are the Foundation of Efficacy Dr. Isaac Bright, Chief Executive Officer, RubrYc Therapeutics, Inc, USA |
| 16:30-16:50 |
Title: The Strep-tag Technology - The Superior Tag System for the Entire Protein Production Workflow Dr. Dennis Karthaus, Director Protein Products and Assays, IBA GmbH, Germany |
| 16:50-17:10 |
Title: Accelerated Protein Development with Integrated Cell Free Expression, Purification, and Bioconjugation, Evaluated with Time-gated Raman Dr. Marco G Casteleijn, Senior Scientist, VTT Technical Research Centre of Finland Ltd., Finland |
|
Session 311: Cancer Drug Targets |
|
|
Day 1: Afternoon, July. 15, 2022 |
|
|
Chair |
Dr. Laszlo Takacs, Member of the Hungarian Academy of Sciences, Laboratory of Monoclonal Antibody Proteomics, Department of Human Genetics, University of Debrecen, Hungary |
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: Epitome Level Screening Delivers New Drug Targets beyond Proteins Dr. Laszlo Takacs, Member of the Hungarian Academy of Sciences, Laboratory of Monoclonal Antibody Proteomics, Department of Human Genetics, University of Debrecen, Hungary |
|
14:00-14:25 |
Speech Opportunity Available |
|
14:25-14:50 |
Speech Opportunity Available |
|
14:50-15:15 |
Title: Targeting Human G-quadruplex Formed by Telomeric DNA and C9orf72 Hexanucleotide Repeats Dr. Guang Zhu, Professor, The Hong Kong Univ. of Sci. and Tech., Hong Kong, China |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: Breaking Steroid Resistance by Targeted Compounds in Pediatric T-cell Acute Lymphoblastic Leukemia Dr. Jules P. P. Meijerink, Principal Investigator, Princess Maxima Center for Paediatric Oncology, the Netherlands |
|
15:55-16:20 |
Title: Arsenic Trioxide is Effective in Treating T-ALL and Synergistic Effect when Combined with Ruxolitinib Dr. Sin Chun Fung, Assistant Professor, University of Hong Kong, Hong Kong, China |
|
16:20-16:45 |
Title: The Role of TGFb-regulated microRNAs and LIN28B in Pancreatic Adenocarcinoma Progressions Dr. Leandro Castellano, Honorary Senior Lecturer, University of Sussex, UK |
|
16:45-17:10 |
Title: Small But Mighty; The Cutting-Edge Role of PD-L1 Small Molecule Inhibitors in Cancer Dr. Hend M El Tayebi, Associate Professor, German University in Cairo, Egypt |
|
Session 321: Open Innovation in Drug Discovery |
|
|
Day 1: Afternoon, July. 15, 2022 |
|
|
Chair |
Dr. Florian Montel, Head of opnMe.com & CNS Project Leader, Boehringer Ingelheim, Germany |
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: TBD Dr. Yoshinori Ikeura, CEO, Axcelead Drug Discovery Partners, Inc., Japan |
|
14:00-14:25 |
Title: opnMe.com, The Boehringer Ingelheim Open Innovation Portal to Reach out to New Biology: 2 years of Experience and Perspectives for the Next 3 Years Dr. Florian Montel, Head of opnMe.com & CNS Project Leader, Boehringer Ingelheim, Germany |
|
14:25-14:50 |
Speech Opportunity Available |
|
14:50-15:15 |
Title: MAPK Cascade as a Drug Target for the Prevention of Adhesive Disease Dr. Mikhail Shurygin, Research Director, Pharmasyntez, Russia |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55
|
Speech Opportunity Available |
|
15:55-16:20
|
Speech Opportunity Available |
|
16:20-16:45
|
Title: A Quantum-Inspired Approach to De-Novo Drug Design Ms. Ellen Devereux, Digital Annealer Consultant, Fujitsu, UK |
|
Session 411: Cancers/Tumors |
|
|
Day 1: Afternoon, July. 15, 2022 |
|
|
Chair |
Dr. Luana Pesco Koplowitz, Chief Medical & Scientific Officer, DUCK FLATS Pharma, USA |
| Co-Chair | Dr. Hidemitsu Nakagawa, President, Nozaki Tokushukai Hospital, Japan |
|
Time |
Speeches and Speakers |
|
13:30-13:35 |
Chair's Introduction |
|
13:35-13:55 |
Title: Radioactive Tracer Technology Applied to Clinical Pharmacology -a Historical Review based on Personal Experiences in Japan with Future Perspectives Dr. Yasuhito Sasaki, Director, Research Center for Radiation Oncology, Shonankamakura General HospitalAffiliated Clinical Research Center; Visiting Professor, Graduate School of Yokohama City University, Japan |
|
13:55-14:15 |
Title: Chemotherapeutic Treatment of Infants with Cancer: Challenges and Opportunities Dr. Luana Pesco Koplowitz, Chief Medical & Scientific Officer, DUCK FLATS Pharma, USA |
|
14:15-14:35 |
Title: Melatonin as an Antioxidant and Anti-cancer Agent: Directing it to the Mitochondria Dr. Russel J Reiter, Professor, UT Heath, USA |
| 14:35-14:55 |
Title: Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytoxicity and DNA Cross-Linking in Cancer Cells from Combination of Doxorubicin and Formaldehyde Dr. Ben Barthel, Scientist, University of Colorado, USA |
| 14:55-15:15 |
Title: Advancements in Multidisciplinary Management of HPV Associated Oropharyngeal Cancer Dr. Michael L. Hinni, Chair of Otolaryngology, Mayo Clinic, USA |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:50 |
Title: Intrathecal Sodium Butyrate for Malignant Brain Tumors and Lleptomeningeal Metastasis of Malignant Tumors-experimental Research and Clinical Trial Dr. Hidemitsu Nakagawa, President, Nozaki Tokushukai Hospital, Japan |
|
15:50-16:10 |
Title: TBD Dr. Robert Huigens, Assistant Professor, University of Florida, USA |
|
16:10-16:30 |
Title: HA Conjugated Drugs in Cancer Therapy Dr. James Neil Hunter, International Healthcare Activities Director, Holy Stone Biotech Co Ltd, UK |
|
16:30-16:50 |
Title: Methylglyoxal: A Non Toxic and Potent Therapeutic Agent for Triple Negative Breast Cancer Dr. Manju Ray, Professor, Department of Biophysics, Bose Institute, India |
| 16:50-17:10 |
Title: Aurora Kinase A Inhibitor (VX 680) Inhibits Cell Migration, Invasion, Proliferation and Viability and Promotes Cell Apoptosis in Human Prostate Cancer (PC3) Cells Dr. Ahmad Al-Azayzih, Assistant Professor, United Arab Emirates University, Al Ain, United Arab Emirates |
| 17:10-17:30 |
Speech Opportunity Available |
|
Session 421: Immunotherapy |
|
|
Day 1: Afternoon, July. 15, 2022 |
|
|
Chair |
Dr. Barbara Metzler, Head of Biology, Topas Therapeutics GmbH, Germany |
| Co-Chair | Dr. Erminia Massarelli, Associate Professor, City of Hope, USA |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Keynote Speech Title: NKTR-255: A Potent NK and CD8 Memory T cell Mobilizer Dr. Loui Madakamutil, VP, Head of Discovery, Nektar Therapeutics, USA |
|
14:00-14:25 |
Title: Aviscumine-Another Immunotherapeutic Principle for The Treatment of Cancer Dr. Hans Lentzen, VP Strategy and Innovation, LioniX International BV, the Netherlands |
|
14:25-14:50 |
Title: The Use of Liver-targeting Nanoparticles to Induce Antigen-specific Immune Regulation Dr. Barbara Metzler, Head of Biology, Topas Therapeutics GmbH, Germany |
|
14:50-15:15 |
Speech Opportunity Available |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: Bispecific T-Cell Engagers: Overview of Amgen‘s BiTE® Pipeline Dr. Benno Rattel, Executive Director, Nonclinical Development, Amgen Research, Germany |
|
15:55-16:20 |
Title: Novel Approach with Immunotherapy Combinations in Head and Neck and Non-small Cell Lung Cancers Dr. Erminia Massarelli, Associate Professor, City of Hope, USA |
|
16:20-16:45 |
Title: The Deep Impact of Translational Sciences in CAR T Cell Therapy Advancement Dr. Jan Joseph (Jos) Melenhorst, Professor of Pathology & Laboratory Medicine; Director, Parker Institute for Cancer Immunotherapy Biomarker Program, University of Pennsylvania, USA |
|
16:45-17:10 |
Title: Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms Dr. Li Zhang, Professor and Senior Scientist, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Canada |
© 2003-2022 All rights reserved by BITeomics |